BRAF Multiplex Mutation Screening Kit

BRAF mutations have been identified in various tumor types, such as melanoma (50–60%), colorectal (10%), thyroid (30–50%), and non-small cell lung cancer (NSCLC) (3%), as well as hairy cell leukemia (100%).

Cancer is a genetic disease with uncontrolled growth of abnormal cells. Some types of cancer are frequently associated with specific genetic mutations. Those mutations provide the biomarkers that allow more specific cancer treatments, known as targeted therapy.

Targeted therapy is a newer type of cancer treatment that offers patients the opportunity to use a drug that has a greater effect on cancerous tissue, reducing many of the side effects associated with standard therapy. Therefore, it is a critical step towards targeted therapy by identifying the cancer mutations with a precise and sensitive method.